Olema Pharmaceuticals Inc.
OLMA | NASDAQ
$9.64
-$0.18 (-1.83%)
At close: Sep 21, 2026, 4:00 PM ET
$9.74
+$0.10 (+1.04%)
After-hours:
Sep 21, 2026, 7:43 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 11K |
Gross Profit | n/a | n/a | n/a | n/a | n/a | -11K |
Operating Income | -178.7M | -142.26M | -104.96M | -106.99M | -71.49M | -21.53M |
Interest Income | 16.22M | 12.68M | 8.32M | 2.23M | 442K | 60K |
Pretax Income | -162.45M | -129.47M | -96.66M | -104.79M | -71.1M | -22.12M |
Net Income | -162.45M | -129.47M | -96.66M | -104.79M | -71.1M | -22.12M |
Selling & General & Admin | 21M | 17.74M | 18.82M | 24.71M | 20.39M | 7.82M |
Research & Development | 157.7M | 124.52M | 86.14M | 82.27M | 51.1M | 13.7M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 178.7M | 142.26M | 104.96M | 106.99M | 71.49M | 21.52M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 653K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 178.7M | 142.26M | 104.96M | 106.99M | 71.49M | 21.53M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 87.01M | 58.74M | 45.25M | 40M | 39.52M | 39.31M |
Shares Outstanding (Diluted) | 87.01M | 58.74M | 45.25M | 40M | 39.52M | 39.31M |
EPS (Basic) | -1.87 | -2.20 | -2.14 | -2.62 | -1.79 | -0.58 |
EPS (Diluted) | -1.87 | -2.20 | -2.14 | -2.62 | -1.79 | -0.58 |
EBITDA | -161.96M | -129.08M | -96.28M | -104.43M | -70.93M | -21.52M |
EBIT | -162.45M | -129.47M | -96.66M | -104.79M | -71.1M | -21.47M |
Depreciation & Amortization | 490K | 393K | 377K | 357K | 163K | 11K |
Add to Watchlist
Select watchlists to add or remove OLMA